Nerisopam (GYKI-52322, EGIS-6775) is a drug which is a 2,3-benzodiazepine derivative, related to tofisopam. It has potent anxiolytic and neuroleptic effects in animal studies.[1][2][3]

Nerisopam
Clinical data
ATC code
  • none
Identifiers
  • 4-(7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepin-1-yl)aniline
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H19N3O2
Molar mass309.369 g·mol−1
3D model (JSmol)
  • O(c1c(OC)cc/2c(c1)C/C(=N\N=C\2c3ccc(N)cc3)C)C
  • InChI=1S/C18H19N3O2/c1-11-8-13-9-16(22-2)17(23-3)10-15(13)18(21-20-11)12-4-6-14(19)7-5-12/h4-7,9-10H,8,19H2,1-3H3 checkY
  • Key:WWQDEXGFYVSTCX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

See also

edit

References

edit
  1. ^ Horváth K, Andrási F, Berzsenyi P, Pátfalusi M, Patthy M, Szabó G, Sebestyén L, Bagdy E, Körösi J, Botka P (August 1989). "A new psychoactive 5H-2,3-benzodiazepine with a unique spectrum of activity". Arzneimittel-Forschung. 39 (8): 894–9. PMID 2573361.
  2. ^ Horváth K, Andrási F, Botka P, Hámori T (1992). "Anxiolytic profile of girisopam and GYKI 52,322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone". Acta Physiologica Hungarica. 79 (2): 153–61. PMID 1363928.
  3. ^ Palkovits M, Baffi JS, Berzsenyi P, Horváth EJ (July 1997). "Anxiolytic homophthalazines increase Fos-like immunoreactivity in selected brain areas of the rat". European Journal of Pharmacology. 331 (1): 53–63. doi:10.1016/s0014-2999(97)01008-x. PMID 9274930.